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E-mail address: Barbara.Nicholl@manchester.ac.ukChronic widespread pain (CWP) is associated with poor health-related quality of life (HRQoL). It is unclear
whether pain itself is the cause of poor HRQoL or other factors play a role. We hypothesised that new
onset of CWP was associated with poor physical and mental HRQoL but that psychosocial risk markers
for CWP onset would explain this relationship. A prospective population-based survey measured pain
and psychosocial status at baseline. Subjects free of CWP at baseline were followed up 15 months later,
when pain status, threatening life events and HRQoL (SF-12) were assessed. The risk associated with the
new onset of CWP and reporting poor SF12-MCS and SF12-PCS was quantiﬁed using multinomial logistic
regression (relative risk ratios (RRRs) with 95% conﬁdence intervals (95% CI)), adjusted for age and gen-
der. 3000 subjects (77%) free of CWP at baseline participated at follow-up. 2650 subjects (88%) provided
full SF-12 and pain data and formed the cohort for this analysis. 9.4% of subjects (n = 248) reported new
CWP. New CWP was associated with an increased risk of having the poorest SF12-MCS (RRR = 2.3; 95% CI
1.6–3.2) and SF12-PCS (RRR = 8.0; 95% CI 5.4–11.8) scores. After adjusting for baseline psychosocial sta-
tus, the relationship between CWP onset and SF12-MCS was attenuated (RRR = 1.2; 95% CI 0.8–1.8),
although the association with SF12-PCS remained (RRR = 4.8% CI 3.1–7.47). New onset of CWP is associ-
ated with poor mental and physical HRQoL. However, the relationship with mental HRQoL is explained by
psychosocial risk markers.
 2008 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Quality of life is a broad, multifactorial construct that assesses
the degree of well-being felt by individuals and can vary with dif-
ferent cultural inﬂuences [33]. Health-related quality of life
(HRQoL) is one aspect of this construct and although lacking in a
singular deﬁnition [30], it is generally accepted as being concerned
with the effect an individual’s health status has on their subjective
physical, mental, emotional and social well-being [34]. The impor-
tance of the impact of musculoskeletal pain on HRQoL has been
highlighted in The Bone and Joint Decade initiative (2000–2010)
that aims ‘‘to improve the HRQoL for people with musculoskeletal
disorders throughout the world” [45].
Painful musculoskeletal disorders, including ﬁbromyalgia, a dis-
order characterised by chronic widespread pain (CWP), are associ-
ated with poor HRQoL [5,6,18,21]. Although levels of disability are
similar between patients with ﬁbromyalgia and rheumatoid arthri-tudy of Pain. Published by Elsevie
: +44 161 2755043.
(B.I. Nicholl).tis (RA) [14,21,29] quality of life, particularly mental HRQoL, has
been reported to be poorer in ﬁbromyalgia patients [3,6,28,37].
The largest study of HRQoL in musculoskeletal disorders that com-
pared patients with osteoarthritis of the hip, osteoporosis, RA and
ﬁbromyalgia, found reduced physical functioning in all disorders
compared to healthy controls [28]. However, ﬁbromyalgia was
the only disorder to have signiﬁcantly poorer scores on all mental
health dimensions assessed using the Short Form-36 (SF-36) ques-
tionnaire [28]. A cross-sectional study reported a strong associa-
tion between ﬁbromyalgia and HRQoL and found that HRQoL in
ﬁbromyalgia patients was linked with self-reported disability lev-
els [38]. Interestingly in the same study, the authors noted that
mental health, as measured by the SF-36, explained the largest
proportion of variance in the disability levels of ﬁbromyalgia
patients.
Poor psychosocial status has repeatedly been identiﬁed as a risk
marker for the onset of ﬁbromyalgia and CWP [11,20,23]. Our
group has previously reported that subjects with high levels of ill-
ness behaviour and somatic symptoms had an increased risk of
developing CWP [23]. We have also reported that high levels ofr B.V. Open access under CC BY-NC-ND license.
120 B.I. Nicholl et al. / PAIN 141 (2009) 119–126psychological distress observed in subjects with CWP were ex-
plained by factors associated with CWP, including somatic symp-
toms and fatigue, rather than the pain per se [24]. Depression
has been shown to be correlated with HRQoL in ﬁbromyalgia pa-
tients [35]. It is possible that among subjects with new onset of
CWP, those with premorbid psychosocial symptoms may be more
likely to report poor HRQoL.
The aim of this study was to test the hypothesis that new onset
of CWP was associated with both poor mental and physical HRQoL,
and that psychosocial risk markers for CWP onset, which are ame-
nable to intervention, would explain these relationships.2. Methods
2.1. Study design and subjects
A prospective population-based survey was conducted. Partici-
pants aged between 25 and 65 years were contacted via the regis-
ters of three primary care practices located in socio-economically
diverse areas of North-West England. Subjects free of CWP at base-
line who were eligible for follow-up (agreed to further contact and
who had neither moved nor died in the interim period) were in-
vited to take part in a second survey 15 months later.
2.2. Pain ascertainment
Subjects who answered positively to the question ‘‘During the
past month have you experienced any ache or pain which has
lasted for one day or longer?” were asked to shade on a body man-
ikin (four ﬁgures: front, back, left and right sides) any area where
they had experienced this pain. A further question asked whether
they had been aware of these pains for more than 3 months.
Trained observers coded the reported pain data using the deﬁni-
tion of CWP in the American College of Rheumatology criteria for
ﬁbromyalgia (pain experienced in contralateral quadrants of the
body above and below the waist and in the axial skeleton that
has persisted for more than 3 months) [44]. The pain status of par-
ticipants was ascertained using identical methods at both baseline
and follow-up. Based upon these reports, subjects were classiﬁed
into one of two groups – those with new onset of CWP and those
remaining free of CWP.
2.3. Baseline questionnaire
The baseline questionnaire included a number of validated psy-
chosocial scales:
2.3.1. General health questionnaire (GHQ) [9]
The GHQ is a measure of psychological distress. This version
consists of 12 items (e.g. ‘‘in the past few weeks have you felt con-
stantly under strain?”), each answered on a four point scale. For
scoring purposes each response is dichotomised (0 = not at all/no
more than usual or 1 = rather more/much more than usual) and
then the 12 items are summed, giving a total GHQ score of between
0 and 12. A higher score on the GHQ is representative of higher lev-
els of psychological distress.
2.3.2. Estimation of sleep problems scale [15]
This is a 4-item scale which assesses an individuals sleep
problems in the past month. The questions cover the following
components of sleep: onset, maintenance, wakefulness and non-
restorative sleep. Each response is scored from 0 to 5 (not at all
to 22–31 days per month). These are then summed giving a total
sleep problems score of between 0 and 20, with a higher score
representing increased levels of sleep disturbance.2.3.3. Illness attitude scales (IAS) [17]
The IAS were designed to assess fears, attitudes and concerns
about illness behaviour and health. A principal components analy-
sis demonstrated that the IAS measures two particular dimensions,
‘‘health anxiety” and ‘‘illness behaviour” [31]. The health anxiety
subscale consists of 11 items (such as ‘‘are you worried that you
may get a serious illness in the future?”), each scored between 0
and 4, providing a total score of between 0 and 44 (general popu-
lation mean score of 9.1 (standard deviation 6.9)). The illness
behaviour subscale contains six items (such as ‘‘how often do
you see a doctor?”) with a total score ranging from 0 to 24 (general
population mean score of 4.7 (standard deviation 4.2)).
2.3.4. Hospital anxiety and depression scale (HAD) [46]
The HAD is a 14-item scale, scored on a four-point likert scale,
that was originally developed for use in patients with physical ill-
ness. Seven items measuring anxiety and seven measuring depres-
sion, over the last week, provide a total score of between 0 and 21
for each subscale. Higher scores on each scale represent an in-
creased probability of an anxiety or depressive disorder being pres-
ent, respectively.
2.3.5. Somatic Symptoms Checklist [26]
The Somatic Symptoms Checklist is a validated scale originally
developed as a tool to diagnose somatisation disorder by screening
for a lifetime history of seven different items (yes or no answers).
These items include troubled breathing, frequent pain in ﬁngers or
toes, frequent vomiting (when not pregnant), loss of voice, loss of
memory and difﬁculty swallowing. A further seventh item, fre-
quent trouble with menstrual cramps, is included for female par-
ticipants. To avoid spurious associations with CWP onset, neither
of the ‘‘pain” questions were included in the total score for this
analysis. A third question, ‘‘have you ever had difﬁculties swallow-
ing or had an uncomfortable lump in your throat that stayed with
you for at least an hour?” was also excluded from the analysis due
to a high proportion of missing answers. The total score is equal to
the number of symptoms present and therefore ranged from 0 to 4.
2.4. Follow-up questionnaire
At follow-up, HRQoL and threatening life events were assessed.
2.4.1. Short-Form 12 (SF-12) [41]
This was the primary outcome of the study. The SF-12 is a val-
idated shortened version of the SF-36 [25], an inventory originally
designed to assess health status in the Medical Outcomes Study
[25]. The 12 questions gather information on eight health concepts
including, physical functioning, role limitations due to physical and
emotional health, mental health, bodily pain, general health, vital-
ity and social functioning. These items are then scored using a
norm-based method providing a component summary scale score
for both mental (SF12-MCS) and physical (SF12-PCS) HRQoL [42].
Scores range between 13–69 and 10–70 for the SF12-PCS and
SF12-MCS scales, respectively, for the general USA population
[42]. A lower score on the summary scales represents a poorer
HRQoL. The SF-36, the parent of the SF-12, has been found to be
a valid measure of generic HRQoL in musculoskeletal disorders
[12] and the SF-12 has been used in other population-based studies
of pain in the past [7].
2.4.2. Threatening life events inventory [4]
This inventory is a modiﬁed version of Tennant and Andrew’s
1976 67-item life events inventory [36]. This shortened inventory
asks about the occurrence of 12 events in the past 6 months that
are associated with a long-term psychological threat. This list in-
cludes unemployment, ﬁnancial crisis, problems with the police
Eligible for follow-up participation
n = 3875
Follow-up questionnaire sent* 
n = 4197
Deceased or moved
n = 322
Non-participants
n = 875 (22.6%)
Incomplete 
participants†
n = 350 
(11.7%)
Full  
participants† †
n = 2650 
(88.3%)
CWP free
n = 2402 
(90.6%)
CWP onset
n = 248 
(9.4%)
Participants
n = 3000 (77.4%)
Fig. 1. Flowchart of study participation. *Questionnaire sent to subjects who were
free of CWP at baseline. Incomplete participants include subjects who completed
only a short or telephone questionnaire at follow-up, who did not provide complete
SF-12 or pain data at follow-up. Full participants completed a long questionnaire
and provided complete pain and SF-12 data.
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events experienced is summed, providing a total score of 0–12.
2.5. Data collection and statistical analysis
An intensive mailing strategy was used at both timepoints in or-
der to achieve a high level of participation. Subjects who did not
respond to the ﬁrst questionnaire were contacted at fortnightly
intervals with a reminder postcard, and if necessary a second
questionnaire.
We were interested in subjects free of CWP at baseline and their
subsequent CWP status at follow-up. Mental and physical HRQoL,
as measured by the SF-12, were the outcomes of interest. For anal-
ysis purposes, participants’ scores on the SF12-MCS and SF12-PCS
were categorised into tertiles: lowest third = poor HRQoL, middle
third = moderate HRQoL and highest third = good HRQoL (referent
group). Similarly, baseline psychosocial measures (except the So-
matic Symptoms Checklist) and follow-up threatening life events
were categorised into tertiles with good psychosocial state (lowest
third of scores on these scales) as the referent group, the middle
and highest thirds on these scales represented moderate and poor
psychosocial state, respectively. Due to the distribution of its
scores, the Somatic Symptoms Checklist was dichotomised into
subjects reporting 0 symptoms or 1–4 symptoms. Initial descrip-
tive statistics (chi-squared and Kruskal–Wallis tests) were used
to describe study subjects characteristics with regard to their
HRQoL status.
Univariate multinomial logistic regression was used to quantify
the relationship between new onset of CWP at follow-up and SF12-
MCS and SF12-PCS scores. We were also interested in whether
baseline psychosocial risk markers, and follow-up threatening life
events (assessed for the 6-months prior to follow-up), that predict
the onset of CWP were associated with poor SF12-MCS and SF12-
PCS scores, and quantiﬁed each of these relationships using the
same univariate multinomial method. To determine the relative
contributions of new onset of CWP and baseline psychosocial fac-
tors, and follow-up threatening life events, to SF12-MCS and
SF12-PCS scores, a parsimonious multivariate model was con-
structed. To do so, all variables were included in a multivariate
model and a manual backward elimination procedure was used.
This involves removing the predictor variables one at a time and
testing the signiﬁcance of the ‘‘saturated” model (i.e. includes all
variables) against the ‘‘unsaturated” model (i.e. minus the ex-
cluded variable), using a log likelihood ratio test. Variables were
excluded if p > 0.05. Independent of the strength of the relationship
CWP was retained in the model. Results are presented as relative
risk ratios (RRRs) with 95% conﬁdence intervals (95% CI). The
RRR represents the risk of a poor or moderate HRQoL amongst ex-
posed subjects (e.g. those scoring in the moderate or poorest thirds
of the illness behaviour scale) compared to the risk in the unex-
posed subjects (those scoring in the lowest third). Factors were
considered to be associated when the RRRP 1.5 or when the
RRR < 0.67, this signiﬁcant cut-off has been used previously [13].
The ﬁnal stage of analysis was concerned with whether any ob-
served relationships with SF12-MCS and SF12-PCS scores could
be explained by a worsening in pain from baseline. Thus the ﬁnal
parsimonious multivariate regression models were adjusted for
baseline pain status (i.e. reporting no pain or some pain at
baseline). All univariate and multivariate logistic regression
models were adjusted for age and gender. Statistical analysis was
carried out using the statistical software package STATA (version
9) [32].
Ethical approval for this study was awarded by both the Local
Research Ethics Committees (South Manchester and East Cheshire)
and the University of Manchester. All subjects provided written in-
formed consent to participate in the study.3. Results
Fig. 1 summarises the participation of subjects from baseline to
follow-up. A total of 77% (n = 3000) of subjects who were free of
CWP at baseline and eligible for follow-up participated at the sec-
ond stage of the study. However, 12% (n = 350) of these subjects
did not provide SF-12 and/or pain information in their follow-up
questionnaire. This analysis is therefore concerned with the 2650
participants (88%) who provided full data.
3.1. Characteristics of study subjects
The prevalence of CWP at follow-up was 9.4% (n = 248). The
median age of subjects was 46.8 years (95% CI 46.0–47.5) and
55.7% (n = 1476) were female. The SF12-MCS scores ranged from
7.4 to 69.0, the median score was 53.0 (95% CI 52.7–53.3). This
was categorised into thirds for analysis purposes: good = 55.7–
69.0, moderate = 47.5–55.6, and poor = 7.4–47.4. The range of
scores for SF12-PCS was 14.6–66.1, and median score 53.8 (95%
CI 53.6–54.2). The thirds of the SF12-PCS were good = 55.4–66.1,
moderate = 48.6–55.3, and poor = 14.6–48.5.
3.2. Association between age and gender and HRQoL
Table 1 shows the associations between age, gender, CWP status
and psychosocial measures having poor, moderate and good SF12-
MCS and SF12-PCS scores. Age was signiﬁcantly different between
each of the three levels of both SF12-MCS and SF12-PCS scales
(p < 0.01). Older subjects had poorer SF12-PCS scores, whereas
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122 B.I. Nicholl et al. / PAIN 141 (2009) 119–126younger subjects had the poorest SF12-MCS scores. A greater pro-
portion of females reported poor SF12-MCS and SF12-PCS scores.
3.3. Association between pain status and HRQoL
SF12-MCS and SF12-PCS scores were signiﬁcantly poorer in
subjects with new onset of CWP compared to those who remained
free of the disorder. Median scores were: SF12-MCS = 49.5 (95% CI
47.3–51.7) and 53.1 (95% CI 53.0–53.5), respectively; SF12-
PCS = 45.5 (95% CI 43.2–47.2) and 54.2 (95% CI 53.9–54.4), respec-
tively. Table 1 shows the breakdown of scores for the three catego-
ries of SF12-MCS and SF12-PCS.
Subjects with some pain at baseline were signiﬁcantly more
likely to have poor SF12-MCS and SF12-PCS scores compared to
those subjects who reported having no pain (Table 1).
3.4. Association between psychosocial risk markers and HRQoL
High levels, representing a poor psychosocial state, of illness
behaviour, health anxiety, psychological distress (GHQ), anxiety,
depression, life events, sleep problems and reporting one or more
somatic symptoms were associated with both poor SF12-MCS
and SF12-PCS scores (p < 0.01) (Table 1). There was no signiﬁcant
statistical interaction between poor scores on ‘‘mood” variables
(depression, anxiety, illness behaviour, health anxiety and psycho-
logical distress) and sleep or somatic symptoms, in predicting poor
SF12-MCS or SF12-PCS scores.
3.5. Relationship with SF12-MCS
Subjects with new onset of CWP were twice as likely (RRR = 2.3;
95% CI 1.6–3.2) to have the poorest SF12-MCS scores compared to
subjects free of CWP at follow-up (Table 2). This relationship was
not observed for the moderate SF12-MCS category. Scoring in the
moderate and poor category of all the psychosocial measures put
subjects at an increased risk of having a moderate or poor SF12-
MCS score at follow-up.
All signiﬁcant associations were included in a multivariate
model, and backward elimination was used to achieve the most
parsimonious model. Variables that remained in this model are re-
ported in Table 2. After adjustment for baseline psychosocial status
CWP onset was no longer associated with SF12-MCS score
(RRR = 1.2; 95% CI 0.8–1.8). However, subjects scoring in the mod-
erate or poorest third of the GHQ, life events inventory, illness
behaviour, health anxiety, HAD depression and HAD anxiety scales
were all signiﬁcantly more likely to report having the poorest
SF12-MCS score compared to subjects scoring in the best third of
these scales. The strongest of these relationships were observed
with anxiety and depression, with subjects scoring in the poorest
category of these scales being 4 (RRR = 4.1; 95% CI 2.8–6.1) and 5
(RRR = 5.4; 95% CI 3.5–8.4) times more likely to have the poorest
SF12-MCS score, respectively.
3.6. Relationship with SF12-PCS
There was a signiﬁcant increased risk of scoring in the moderate
or poor categories of the SF12-PCS at follow-up in subjects who
had new onset of CWP compared to those free of the disorder:
RRR = 2.1; 1.4–3.2 and RRR = 8.0; 95% CI 5.4–11.8, respectively
(Table 3). Subjects in the poorest two categories of sleep problems,
anxiety, depression and life events were at an increased risk of
having the poorest SF12-PCS scores. However, poor scores of health
anxiety and illness behaviour, and reporting one or more somatic
symptoms, put subjects at an increased risk of having either
moderate or poor SF12-PCS scores.
Table 2
Multinomial logistic regression analysis of the association between baseline psychosocial measures and CWP onset with SF12-MCS scores.
Factor Category Univariate analysisa Multivariate analysisa
Moderate (47.5–55.6) n = 935 Poor (7.4–47.4) n = 790 Moderate (47.5–55.6) n = 935 Poor (7.4–47.4) n = 790
RRR 95% CI RRR 95% CI RRR 95% CI RRR 95% CI
CWP onset CWP free 1 – 1 – 1 – 1 –
CWP 1.2 0.8–1.7 2.3 1.6–3.2 0.9 0.6–1.4 1.2 0.8–1.8
GHQ 0 1 – 1 – 1 – 1 –
1–3 2.2 1.8–2.8 4.4 3.5–5.5 1.6 1.2––2.0 2.1 1.5–2.8
4–12 2.5 1.9–3.3 13.4 10.2–17.5 1.1 0.8––1.7 2.2 1.4–3.3
Sleep problems 0–5 1 – 1 – – – – –
6–11 1.5 1.3–1.9 3.3 2.6–4.2 – – – –
12–20 2.1 1.7–2.6 7.6 6.0–9.7 – – – –
Somatic symptoms 0 1 – 1 – – – – –
1–4 1.6 1.3–2.0 2.2 1.8–2.7 – – – –
Health anxiety 0–7 1 – 1 – 1 – 1 –
8–14 1.5 1.2–1.8 1.8 1.4–2.2 1.3 1.0–1.6 1.3 0.9–1.7
15–44 2.3 1.9–2.9 4.5 3.6–5.7 1.6 1.2–2.1 1.7 1.2–2.4
Illness behaviour 0–5 1 – 1 – 1 – 1 –
6–9 1.3 1.1–1.6 2.3 1.8–2.8 1.2 0.9–1.5 1.7 1.3–2.2
10–22 2.0 1.6–2.6 8.8 6.8–11.3 1.3 0.9––1.8 2.3 1.6–3.4
HAD anxiety 0–5 1 – 1 – 1 – 1 –
6–9 2.3 1.9–2.8 4.1 3.2–5.2 1.7 1.3–2.2 2.2 1.6–3.1
10–21 3.4 2.6–4.3 18.2 14.0–13.5 2.0 1.4–2.8 4.1 2.8–6.1
HAD depression 0–3 1 – 1 – 1 – 1 –
4–6 2.6 2.1–3.2 5.5 4.3–6.9 1.9 1.5–2.5 2.6 1.9–3.6
7–19 3.7 2.8–5.0 24.9 18.7–33.1 2.2 1.5–3.4 5.4 3.5–8.4
Life eventsb 0 1 – 1 – 1 – 1 –
1–2 1.5 1.2–1.8 2.3 1.8–2.8 1.6 1.3–2.0 2.0 1.5–2.6
3–6 1.8 1.4–2.2 5.3 4.2–6.7 1.8 1.4–2.4 3.5 2.6–4.9
Signiﬁcant associations are highlighted in bold text.
a High SF12-MCS category is the referent group; all models are adjusted for age and gender.
b Life events during the 6 months prior to completion of the follow-up questionnaire.
Table 3
Multinomial logistic regression analysis of the association between baseline psychosocial measures and CWP onset with SF12-PCS scores.
Factor Category Univariate analysisa Multivariate analysisa
Moderate (48.6–55.3) n = 947 Poor (14.6–48.5) n = 712 Moderate (48.6–55.3) n = 947 Poor (14.6–48.5) n = 712
RRR 95% CI RRR 95% CI RRR 95% CI RRR 95% CI
CWP onset CWP free 1 – 1 – 1 – 1 –
CWP 2.1 1.4–3.2 8.0 5.4–11.8 1.8 1.2–2.9 4.8 3.1–7.4
GHQ 0 1 – 1 – – – – –
1–3 1.0 0.8–1.2 2.0 1.6–2.5 – – – –
4–12 1.0 0.8–1.3 3.1 2.5–3.9 – – – –
Sleep problems 0–5 1 – 1 – 1 – 1 –
6–11 1.1 0.9–1.3 2.2 1.7–2.7 1.003 0.8–1.3 1.5 1.1–2.0
12–20 1.2 0.99–1.6 5.3 4.2–6.7 1.1 0.8–1.4 1.9 1.4–2.6
Somatic symptoms 0 1 – 1 – 1 – 1 –
1–4 1.5 1.2–1.8 2.7 2.2–3.3 1.3 1.1–1.7 1.7 1.4–2.2
Health anxiety 0–7 1 – 1 – – – – –
8–14 1.2 1.0–1.5 1.2 1.0–1.5 – – – –
15–44 1.4 1.1–1.7 1.9 1.5–2.4 – – – –
Illness behaviour 0–5 1 – 1 – 1 – 1 –
6–9 1.5 1.2–1.8 2.6 2.0–3.2 1.3 1.1–1.7 1.9 1.4–2.5
10–22 1.9 1.5–2.5 14.7 11.2–19.1 1.9 1.4–2.6 7.0 4.9–9.8
HAD anxiety 0–5 1 – 1 – – – – –
6–9 1.1 0.9–1.3 1.6 1.3–2.0 – – – –
10–21 0.99 0.8–1.2 2.8 2.3–3.5 – – – –
HAD depression 0–3 1 – 1 – 1 – 1 –
4–6 1.2 0.98–1.5 2.4 2.0–3.0 1.1 0.9–1.4 1.5 1.2–2.0
7–19 1.2 0.96–1.5 5.4 4.2–6.8 0.9 0.6–1.2 1.4 0.99–1.9
Life eventsb 0 1 – 1 – – – – –
1–2 0.99 0.8–1.2 1.3 1.0–1.6 – – – –
3–6 0.97 0.8–1.2 2.3 1.8–2.8 – – – –
Signiﬁcant associations are highlighted in bold text.
a High SF12-PCS category is the referent group; all models are adjusted for age and gender.
b Life events during the 6 months prior to completion of the follow-up questionnaire.
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category of the SF12-PCS was attenuated in the parsimonious mul-
tivariate model (as shown in Table 3); however, there was still a 2-fold (RRR = 1.8; 95% CI 1.2–2.9) and 5-fold (RRR = 4.8; 95% CI 3.1–
7.4) increased risk of having a moderate or poor SF12-PCS score,
respectively. High levels (scoring in the poorest third) of baseline
Table 4
Comparison of baseline measures between non-participantsa and participants at
follow-up.
Non-participantsa Participants P-valueb
n = 1225 n = 2650
n % n %
Gender
Male 548 44.7 1174 44.3 0.8
Female 677 55.3 1476 55.7
Baseline pain status
No pain 478 39.0 1142 43.1 <0.02
Some pain 747 61.0 1508 56.9
Median 95% CI Median 95% CI
Age 45.7 44.9–46.7 46.8 46.0–47.5 0.02
Psychosocial scales
Sleep problems 5 5–5 5 4–5 0.08
GHQ 1 0–1 0 0–0 <0.01
Somatic symptoms 0 0–0 0 0–0 <0.01
Health anxiety 9 9–10 9 9–9 0.4
Illness behaviour 5 4–5 4 4–4 <0.01
HAD anxiety 6 6–6 5 5–5 <0.01
HAD depression 3 3–3 3 2–3 <0.01
a Non-participants include subjects who were eligible for follow-up (had not
moved or died and had agreed to further contact at baseline) and who did not
complete a questionnaire or provide full information at follow-up.
b All values are by Mann–Whitney U-test except gender and baseline pain status
which are by chi-squared test.
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(RRR = 1.9; 95% CI 1.4–2.6) and reporting one or more somatic
symptoms (RRR = 1.7; 95% CI 1.4–2.2) were also signiﬁcant inde-
pendent predictors of poor SF12-PCS scores. High levels of depres-
sion were moderately associated with poor PCS scores (RRR = 1.4;
95% CI 0.998–1.9), and, although this relationship was not statisti-
cally signiﬁcant, a log likelihood test indicated that it was an
important predictor and should be retained in the model.
3.7. Baseline pain status
Having some pain at baseline was associated with an increased
risk of having CWP at follow-up (RRR = 6.0; 95% CI 4.1–8.8), and
having the poorest SF12-MCS (RRR = 2.1; 95% CI 1.7–2.6) and
SF12-PCS (RRR = 4.8; 95% CI 3.9–6.1) scores at follow-up. The ﬁnal
multivariate models were then adjusted for the presence of some
pain at baseline. The relationship between new onset of CWP and
SF12-MCS did not change (RRR = 1.2 95% CI 0.8–1.8). However,
the risk of subjects with new onset of CWP being in the poorest
third of the SF12-PCS remained, although slightly attenuated
(RRR = 4.0; 95% CI 2.6–6.2).
3.8. Comparison of participants and non-participants at follow-up
Baseline measures were compared for participants (n = 2650)
and non-participants, including subjects who did not respond or
who did not provide complete data at follow-up (n = 1225), these
results are presented in Table 4. Non-participants were more likely
to be younger than participants (p = 0.02) and to report having
some pain at baseline (p = 0.02). Scores on the GHQ, HAD anxiety
and depression, and illness behaviour scales were poorer in non-
participants than participants (p < 0.01). There was also a differ-
ence in somatic symptom scores between groups; however, the
median and 95% CI was 0 and 0–0 for each.
4. Discussion
We have shown that subjects with new onset of CWP have an
increased risk of reporting a poor SF12-MCS score. However, thisrelationship is explained by premorbid psychosocial risk factors
that are associated with the onset of CWP. Anxiety and depression
were the strongest independent predictors of a poor SF12-MCS
score. The onset of CWP was also a signiﬁcant predictor of poor
SF12-PCS score. Although this relationship was partly explained
by illness behaviour, somatic symptoms, depression and sleep
problems, CWP onset remained an independent predictor. Further
adjustment for having some pain at baseline did not explain this
relationship, indicating that a poor SF12-PCS score was not simply
a reﬂection of worsening pain symptoms. These results signify that
poor mental HRQoL observed in subjects with new onset of CWP is
predicted by prior psychosocial status, and that physical HRQoL is
predicted by the onset of CWP, independently of prior poor psy-
chosocial status.
Limitations to our study must be considered before discussing
the importance of our ﬁndings:
(1) The SF-12 was used to assess HRQoL at follow-up. We were
unaware of baseline scores and cannot comment on change
in scores associated with new onset of CWP. SF-12 scores at
follow-up may simply reﬂect baseline scores. Subjects who
developed pain may have had poor baseline SF-12 scores
that may have been due to the presence of disease. Subjects
with an ‘‘organic” disease are likely to experience a reduc-
tion in their quality of life; however, the majority of CWP
cases, up to 76% [22], are not explained by an obvious bio-
logical cause. It is therefore unlikely that approximately
25% of subjects with CWP who have an ‘‘organic” disease
would explain our results.
(2) The psychosocial measures in the current study (including
psychological distress, anxiety and depression) and the SF-
12 as a measure of mental HRQoL are likely tapping into
the same construct. It is possible that baseline psychosocial
factors acted as a proxy for mental HRQoL. It is perhaps
unsurprising that these are the factors that we found to pre-
dict a poor SF12-MCS score at follow-up. The strength of our
study is in demonstrating that in addition to relationships
with baseline psychosocial measures, the onset of CWP does
not independently increase the risk of having a poor SF12-
MCS score.
(3) After adjusting for baseline psychosocial factors, the onset of
CWP remains strongly associated with poor SF12-PCS scores.
Unmeasured confounders (diet, smoking behaviour, alcohol
consumption) may further explain the relationship between
new CWP and SF12-PCS scores. Arguably the most important
unmeasured putative confounder is physical activity levels,
which have previously been shown to be associated with
physical HRQoL in ﬁbromyalgia patients [2].
(4) Co-morbidities are common in subjects with CWP [1]. These
co-morbidities may result in a reduction in HRQoL, indepen-
dently of CWP. The presence of co-morbidities has not been
recorded in the current study, and the possibility that a co-
morbid physical condition resulted in the poor HRQoL
observed in subjects with new onset of CWP at follow-up
remains a possibility.
(5) Non-participants, as expected in postal surveys, were youn-
ger and had higher somatic symptom, GHQ, illness behav-
iour, anxiety and depression scores. Non-participants were
also more likely to report some pain at baseline. Having
some pain at baseline did not change the association
between new onset of CWP and poor MCS scores, and atten-
uated, but did not explain the relationship between CWP
onset and poor PCS scores. It is unlikely that this relationship
would differ in non-participants.
(6) There is likely to be error in classiﬁcation of exposures and
outcome. The psychosocial measures used are well validated
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of this kind. Any misclassiﬁcation of these exposures is likely
to be random across those who did and did not develop
CWP. Therefore any misclassiﬁcation would weaken an asso-
ciation, suggesting that the relationships we have reported
could actually be an under-estimation of the true associa-
tion. The ACR criteria [44] used to deﬁne CWP are the stan-
dard criteria for classiﬁcation of CWP, as such they reﬂect
subjects with a common disorder and allow comparison
between studies involving CWP subjects. It is unlikely that
we will have missed many subjects who developed CWP in
the intervening 15-month period and who subsequently
recovered before follow-up, as CWP is persistent in nature
[27]. However, we will have missed details of speciﬁc inci-
dents that may have occurred during the 15-month period
that could have triggered the onset of CWP, or that have
resulted in a reduction in HRQoL.
Our results show for the ﬁrst time that psychosocial risk mark-
ers for the onset of CWP act as independent risk markers for poor
HRQoL (as measured by the SF-12) observed in subjects with CWP.
The treatment of CWP continues to pressure health care profes-
sionals, both at primary and at secondary levels, here we have
highlighted the importance of non-pain-related factors that could
be targeted in order to improve HRQoL in subjects with CWP. A
prospective study of low back pain patients reported that anxiety
and depression, as well as fear avoidance related to work and stres-
ses related to back pain, were important predictors of physical
HRQoL 6 months after baseline [16]. Our ﬁndings support the
importance of psychosocial markers in HRQoL outcomes for sub-
jects with chronic pain.
To date treatment interventions for ﬁbromyalgia patients that
have targeted psychosocial markers, including cognitive behav-
ioural therapy (CBT), have resulted in improved pain intensity, psy-
chological status, and physical functioning [10,43]. A CBT
intervention study of 145 ﬁbromyalgia patients randomly assigned
subjects to one of two programmes: (1) standard medical care or
(2) standard medical care plus six sessions of CBT (targeted at
physical function). Twenty-ﬁve percent of subjects in group 2
achieved a signiﬁcant improvement in physical functioning 12
months after baseline, compared to only 12% in group 1 [43]. This
was over a relatively short period although it does suggest the po-
tential of CBT; however, the efﬁcacy and long-term outcome of
such treatments need to be studied in greater detail. The current
study emphasises the importance of targeting markers of psycho-
social status in CBT programmes that may lead to improvements
in both mental and physical HRQoL amongst subjects with CWP.
We have shown that illness behaviour predicts both mental and
physical HRQoL, whereas high levels of health anxiety, psycholog-
ical distress and anxiety are associated speciﬁcally with poor men-
tal HRQoL. Depression which is strongly associated with poor
mental HRQoL is only moderately associated with poor physical
HRQoL. Similarly, sleep problems and somatic symptoms appear
to be speciﬁc to a poor physical HRQoL. These results suggest that
speciﬁc programmes may be required to successfully address the
separate components of HRQoL. Why predictors for mental and
physical components of HRQoL differ is not clear. However, it
seems reasonable that sleep problems and somatic symptoms
would manifest in poorer physical functioning and more ‘‘psycho-
logical” problems, such as anxiety and depression, would have a
more detrimental affect on mental functioning. The nature of ill-
ness behaviour, a measure of hypochondriasis, suggests that it
would affect both mental and physical HRQoL, as the association
with both poor MCS and PCS scores in our study showed.
Mechanisms that may be important in explaining the poor
HRQoL in subjects with CWP include the fear-avoidance modeldeveloped by Vlaeyen and Linton as an explanation for chronic
low back pain [40]. It proposes that when pain is perceived as
threatening then symptoms tend to be catastrophised, resulting
in increased disability and depression. There is also evidence of
‘‘disuse syndrome” [39], where long-term avoidance of daily activ-
ities can result in increased physiological and psychological nega-
tive effects. Patients with chronic pain have been shown to have
greater catastrophic coping strategies than those with acute pain
[8]. It is likely that this ‘‘abnormal” coping strategy in subjects
who are psychologically predisposed to CWP will also put them
at a higher risk of having poor HRQoL.
It has yet to be shown whether the psychosocial factors which
predict poor HRQoL also predict a continued poor quality of life
in subjects with CWP. How HRQoL changes overtime in subjects
with the disorder may be associated with the poor outcome these
subjects have, including a higher risk of mortality [19]. Prioritising
treatment approaches to CWP and ﬁbromyalgia may help to limit
the detrimental effects the disorder has on the quality of life of
individuals. An in-depth consideration of individual patients cop-
ing strategies and psychological proﬁle may also assist in deter-
mining the most appropriate and, ultimately successful,
treatment path to take.Conﬂict of interest
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